相关实验视频

Updated: May 25, 2025

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

杜尔瓦卢马布单一治疗复杂的晚期肝细胞癌:对无法接受组合免疫治疗的患者进行现实研究

Chihiro Miwa¹, Sadahisa Ogasawara¹, Takuya Yonemoto¹

¹Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.

Cancer medicine

|February 27, 2025

概括

杜尔瓦卢马布单一治疗为无法接受组合免疫治疗的晚期肝细胞癌 (HCC) 患者提供了安全有效的选择. 这项现实研究表明,对于这个具有挑战性的患者群体,有希望的结果.

科学领域:

肝胆道癌症肝胆道癌症
医学瘤学医学瘤学
免疫治疗是一种免疫疗法.

背景情况:

组合免疫疗法是高级肝细胞癌 (HCC) 的标准.
一些HCC患者不能容忍组合免疫疗法.
确定这些患者的替代治疗方法至关重要.

研究的目的:

评估杜尔瓦卢马布单一治疗的安全性和有效性.
在不适合组合免疫治疗的高级HCC患者中评估杜尔瓦卢马布.
分析现实世界队列中的结果,预后因素不佳.

主要方法:

对35名用杜尔瓦卢马布治疗的晚期HCC患者的回顾性分析.
包括标准:不符合组合免疫疗法或VEGF-TKI的资格.
评估结果:总生存率,无进展生存率,客观反应率,疾病控制率和不良事件.

主要成果:

中位数无进展生存期为2.7个月;中位数整体生存期未达到.
客观应答率为2.9%,疾病控制率为51.4%.
与治疗相关的≥3级不良事件发生在8.6%的患者中;由于不良事件而停止治疗的患者为11.4%. 常见的副作用包括AST/ALT升高和低albuminemia. 免疫介导的AE影响率为14.3%.

结论:

杜尔瓦卢马布单一治疗在不适合组合治疗的晚期HCC患者中显示出有利的安全性.
在这个特定的患者群体中,效果似乎与VEGF-TKIs相美.
杜尔瓦卢马布是一种可行的选择,特别是对于患有晚期HCC的Child-Pugh B患者.

关键词:

孩子Pugh B 在孩子Pugh B 慢性脏疾病慢性脏疾病达尔瓦卢马布 (Durvalumab) 是一种耐用药.肝细胞癌是肝细胞癌.免疫疗法免疫疗法现实世界的研究研究.

更多相关视频

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...